In this seminar, David will review history of the pharma industry, drug development and how the technological breakthroughs around DNA led to the birth (and subsequent explosion) of what we now know call the biotech industry. He will then move on to review the history and current status of the Australian Biotech industry and what success looks like from the perspective of an Australian start-up. Key points include:
•Biotech defined
•The birth of biotech
•Biotech vs Pharma intersection
•Biotech today in numbers
•An analysis of the biotech sector in Australia today
•What is success ?
•Analysis of the needs for a successful biotech eco-system.
Meet your Presenter: Dr David Fuller
David Fuller is currently Chief Medical Officer, Aucentra Therapeutics and Chairman of EpiAxis Therapeutics, a privately owned epigenetic therapeutic and diagnostic company, and is a Non-Executive Director of the ASX- listed biotech company, AdAlta (ASX: 1AD). He has more than 30 years of R&D experience, spanning large, mid and small cap companies including pre-clinical and clinical development, medical and regulatory affairs, and commercialisation. Most recently Dr Fuller was the Senior Vice President of Clinical Development in the Oncology Business Unit at Syneos Health Clinical Solutions. Prior to this he was a Director at Linear Clinical Research, Chairman of Dimerix Bioscience, CMO/COO at Trident Clinical Research, CMO at Arana Therapeutics, and Vice-President Clinical at Genzyme Europe